A Phase 1 interventional study of Cobimetinib and Pictilisib in Solid Tumors, sponsored by Genentech, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams \[mg\]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
Drug: Cobimetinib · Drug: Pictilisib
Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
Drug: Cobimetinib · Drug: Pictilisib
Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
Drug: Cobimetinib · Drug: Pictilisib
Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
Drug: Cobimetinib · Drug: Pictilisib
Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
Drug: Cobimetinib · Drug: Pictilisib
Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
Drug: Cobimetinib · Drug: Pictilisib
Repeated oral dosing.
Also known as: GDC-0973, XL518
Repeated oral dosing.
Also known as: GDC-0941
Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B
DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: Grade 3 nausea, vomiting, or diarrhea that resolved to Grade ≤1 within 7 days, Grade 3 rash or Grade ≥3 fatigue that resolved to Grade ≤2 within 7 days, Grade ≥3 hyperglycemia or lipid profile results that occurred during non-fasting conditions, Grade 3 or 4 elevation of serum creatine phosphokinase levels or Grade 3 non clinically significant (as assessed by Investigator) laboratory abnormality that was asymptomatic; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.
Time frame: Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28
Maximum Tolerated Combination Doses of Cobimetinib and Pictilisib During Dose-Escalation Stages 1, 1A and 1B
MTD was determined (by Investigator) based on the DLTs, as well as adverse events (AEs) in dose-escalation Stages 1, 1A, and 1B that did not meet protocol-defined DLT criteria but indicated intolerability of a given dose combination. Separate combination MTDs were determined for each dose-escalation stage. DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.
Time frame: Cohorts 1-3: Day 1 to Day 35, All other cohorts: Day 1 to Day 28
Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours pre-cobimetinib (Pr-C) dose, 0.5, 2, 4, 6 hours post-cobimetinib (Po-C) dose on Day 3, Day 4
Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4
Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Day 3, Day 4
Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours pre-pictilisib (Pr-P) dose, 0.5, 2, 4, 6 hours post-pictilisib (Po-P) dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3
Time frame: 0-4 hours Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Day 1, Day 2, 0-4 hours Pr-C dose on Day 3
Tmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Cmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
AUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 8, Cycle 1 Days 9; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Tmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Cmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
AUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Terminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Apparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).
Time frame: Cohorts 1-3: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2, 22
Tmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
Cmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2, 8, 14
AUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 8, Cycle 1 Day 9; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Tmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Cmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
AUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
t1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
CL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 28, Cycle 1 Day 29, Cycle 2 Days 1, 15, 21; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).
Time frame: Cohorts 1-3: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 8 and 28, Cycle 1 Days 9, 29; Cohorts 4-6A: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Day 2, 22
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 18, Cycle 1 Days 2, 19
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Day 2
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Day 2
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
t1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22
CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 14
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Cmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22
t1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
CL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 21, Cycle 1 Day 22, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts
Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Days 1 and 21, Cycle 1 Days 2 and 22
Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as median.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-C dose, 0.5, 2, 4, 6 hours Po-C dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2, 8, 15-17
AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 1, Cycle 1 Days 2
Tmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Cmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
CL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts
Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
Time frame: Pr-P dose, 0.5, 2, 4, 6 hours Po-P dose on Cycle 1 Day 18, Cycle 1 Day 19, Cycle 2 Days 1, 15, 21
Number of Participants With Best Overall Response - Dose Escalation Stages 1, 1A and 1B
Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) = disappearance of all target and non-target lesions. Partial Response (PR) = at least 30 percent (%) decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. Progressive disease (PD) = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions. Stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment start.
Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)
Duration of Objective Response - Dose Escalation Stages 1, 1A and 1B
Duration of objective response was defined as the time from first occurrence of a documented objective response (CR or PR) until the time of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). CR = disappearance of all target and non-target lesions. PR = at least 30 % decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.
Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)
Progression-Free Survival (PFS) - Dose Escalation Stages 1, 1A and 1B
PFS was the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.
Time frame: Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days)
| Milestone | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 9 | 11 | 10 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 3 | 3 | 9 | 11 | 10 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 2 | 2 | 3 | 4 | 10 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 7 | 9 | 8 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 4 | 7 | 9 | 8 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 5 | 7 | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 3 | 5 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 3 | 3 | 0 | 0 |
| Milestone | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 | 0 |
| Milestone | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S2A Expansion: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31 |
DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: Grade 3 nausea, vomiting, or diarrhea that resolved to Grade ≤1 within 7 days, Grade 3 rash or Grade ≥3 fatigue that resolved to Grade ≤2 within 7 days, Grade ≥3 hyperglycemia or lipid profile results that occurred during non-fasting conditions, Grade 3 or 4 elevation of serum creatine phosphokinase levels or Grade 3 non clinically significant (as assessed by Investigator) laboratory abnormality that was asymptomatic; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.
| participants | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) During Dose Escalation Stages 1, 1A and 1B | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 |
MTD was determined (by Investigator) based on the DLTs, as well as adverse events (AEs) in dose-escalation Stages 1, 1A, and 1B that did not meet protocol-defined DLT criteria but indicated intolerability of a given dose combination. Separate combination MTDs were determined for each dose-escalation stage. DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity; Grade ≥3 febrile neutropenia; Grade ≥4 neutropenia (absolute neutrophil count \<500/microliter) lasting \>5 days; Grade ≥4 thrombocytopenia lasting \>48 hours; Grade ≥4 anemia; Grade ≥3 total bilirubin, hepatic transaminase, alkaline phosphatase, lasting \>72 hours; Grade ≥2 diffusion capacity of the lung for carbon monoxide concomitant with an absolute decrease of ≥20 percentage points from baseline.
| mg | All Participants - Stages 1, 1A, 1B |
|---|---|
| Stage 1: Cobimetinib (n = 44) | 40 |
| Stage 1: Pictilisib (n = 44) | 100 |
| Stage 1A: Cobimetinib (n = 34) | 125 |
| Stage 1A: Pictilisib (n = 34) | 180 |
| Stage 1B: Cobimetinib (n = 20) | NA |
| Stage 1B: Pictilisib (n = 20) | NA |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| Time of Maximum Concentration (Tmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3 | 4.00 (2.0 to 4.0) | 4.00 (4.0 to 4.0) | 2.00 (2.0 to 2.0) |
| nanograms per milliliter (ng/mL) | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3 | 27.6 ± 95 | 16.6 ± 78 | 97.0 ± 63 |
| nonograms*hour per milliliter (ng*h/mL) | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Time 0 to 24 Hours Post-Dose (AUC0-24) of Cobimetinib on Day 3 - Stage 1, Cohorts 1-3 | 392 ± 88 | 279 ± 75 | 1190 ± 53 |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| Tmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3 | 3.00 (2.0 to 24.0) | 4.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) |
| ng/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| Cmax of Pictilisib on Day 1 - Stage 1, Cohorts 1-3 | 162 ± 37 | 185 ± 27 | 280 ± 41 |
| ng*h/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib |
|---|---|---|---|
| AUC0-24 of Pictilisib on Day 1 - Stage 1, Cohorts 1-3 | 1680 ± 16 | 1950 ± 50 | 2680 ± 83 |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 4.00 (2.0 to 4.0) | 4.00 (2.0 to 24) | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) | 4.00 (2.0 to 4.0) | 3.00 (2.0 to 4.0) |
| ng/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 20.2 ± 100 | 17.7 ± 62 | 87.4 ± 73 | 101 ± 63 | 61.0 ± 45 | 131 ± 66 | 138 ± 61 |
| ng*h/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 299 ± 62 | 311 ± 53 | 1320 ± 56.6 | 1300 ± 61 | 957 ± 42 | 2050 ± 71 | 1790 ± 56 |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 6.00 (2.0 to 6.0) | 4.00 (4.0 to 6.0) | 2.00 (2.0 to 24) | 2.00 (2.0 to 4.0) | 4.00 (2.0 to 24) | 3.0 (2.0 to 24) | 4 (NA to NA) |
| ng/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 37.1 ± 5.6 | 52.2 ± 57 | 228 ± 120 | 167 ± 56 | 138 ± 63 | 245 ± 79 | 87.4 ± NA |
| ng*h/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 749 ± 1.4 | 900 ± 70 | 4130 ± 94 | 2410 ± 66 | 2460 ± 57 | 4050 ± 110 | 1120 ± NA |
Half-life is the time measured for the plasma concentration to decrease by one half.
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Terminal Half-life (t1/2) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 49.3 (41 to 60) | 37.9 (32 to 43) | 31.7 (22 to 48) | 34.1 (32 to 37) | 43.2 (34 to 56) | 45.7 (41 to 56) | 40.5 (NA to NA) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liters per hour (L/hr) | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 26.7 ± 1.4 | 22.2 ± 70 | 9.67 ± 94 | 16.6 ± 66 | 16.2 ± 61 | 14.8 ± 110 | 53.6 ± NA |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).
| ratio | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 2.51 ± 63 | 2.89 ± 43 | 3.14 ± 73 | 2.03 ± 36 | 2.90 ± 73 | 2.83 ± 54 | 1.77 ± NA |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) | 2.00 (0.5 to 4.0) | 2.00 (2.0 to 4.0) | 2.00 (0.5 to 4.0) | 2.00 (2.0 to 4.0) |
| ng/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 196 ± 20 | 193 ± 16 | 329 ± 26 | 390 ± 60 | 302 ± 34 | 272 ± 54 | 355 ± 83 |
| ng*h/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3) - Stage 1 All Cohorts | 1660 ± 28 | 2150 ± 43 | 2600 ± 28 | 3360 ± 43 | 2770 ± 43 | 2870 ± 48 | 3240 ± 68 |
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 2.00 (2.0 to 6.0) | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 4.0) | 2.00 (0.5 to 4.0) | 2.00 (2.0 to 6.0) | 2.00 (2.0 to 24) | 2.00 (NA to NA) |
| ng/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 198 ± 38 | 278 ± 100 | 459 ± 20 | 409 ± 49 | 374 ± 69 | 396 ± 48 | 441 ± NA |
| ng*h/mL | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 2500 ± 21 | 2930 ± 150 | 5500 ± 34 | 3890 ± 63 | 4320 ± 58 | 4510 ± 40 | 4070 ± NA |
Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| hours | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| t1/2 of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 25.8 (NA to NA) | — | — | NA (NA to NA) | 24.7 (22 to 30) | 27.7 (22 to 41) | — |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| CL/F of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 32.0 ± 21 | 34.1 ± 150 | 14.5 ± 34 | 25.7 ± 63 | 30.1 ± 58 | 22.2 ± 40 | 24.6 ± NA |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) divided by AUC0-24 at Cycle 1 Day 1 (Cycle 1 Day 8 for Cohorts 1-3).
| ratio | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio of Pictilisib on Cycle 1 Day 21 (Cycle 1 Day 28 for Cohorts 1-3) - Stage 1 All Cohorts | 1.51 ± 47 | 1.36 ± 79 | 2.11 ± 6.0 | 1.16 ± 34 | 1.71 ± 29 | 1.70 ± 25 | 2.8 ± NA |
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts | 2.00 (2.0 to 4.0) | 4.00 (2.0 to 6.0) | 2.00 (1.0 to 2.0) | 4.00 (2.0 to 24) | 4.00 (2.0 to 6.0) | 5.00 (2.0 to 24) | 4.00 (2.0 to 6.0) |
| ng/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts | 301 ± 87 | 137 ± 66 | 436 ± 67 | 184 ± 47 | 275 ± 72 | 333 ± 45 | 311 ± 48 |
| ng*h/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1A All Cohorts | 4950 ± 80 | 2320 ± 61 | 5520 ± 59 | 2620 ± 50 | 4250 ± 75 | 5100 ± 47 | 5090 ± 45 |
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | 5.00 (2.0 to 24) | 3.00 (2.0 to 4.0) |
| ng/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | 802 ± 24 | 372 ± 45 | 616 ± 39 | 204 ± 57 | 409 ± 43 | 475 ± 86 | 682 ± 23 |
| ng*h/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | 13400 ± 18 | 5680 ± 55 | 9990 ± 28 | 3060 ± 50 | 6980 ± 55 | 7740 ± 69 | 11100 ± 23 |
Half-life is the time measured for the plasma concentration to decrease by one half.
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | NA (NA to NA) | 46.1 (32 to 67) | 47.4 (34 to 63) | 48.8 (37 to 63) | 48 (36 to 72) | NA (NA to NA) | 46.2 (33 to 55) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | 7.49 ± 18 | 17.6 ± 55 | 12.5 ± 28 | 40.9 ± 50 | 17.9 ± 55 | 19.4 ± 69 | 13.6 ± 23 |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 1A All Cohorts | 2.70 ± 57 | 2.44 ± 60 | 1.46 ± 30 | 1.11 ± 67 | 1.52 ± 120 | 1.75 ± 40 | 1.84 ± 8.1 |
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 24) | 2.00 (2.0 to 4.0) | 2.00 (0.5 to 6.0) | 4.00 (0.5 to 6.0) |
| ng/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts | 547 ± 80 | 408 ± 190 | 390 ± 76 | 367 ± 61 | 832 ± 35 | 619 ± 110 | 514 ± 81 |
| ng*h/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1A All Cohorts | 6900 ± 62 | 4900 ± 170 | 3670 ± 72 | 4280 ± 48 | 8440 ± 32 | 5650 ± 88 | 6680 ± 53 |
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | 2.00 (2.0 to 4.0) | 2.00 (2.0 to 2.0) | 2.00 (0.5 to 2.0) | 2.00 (2.0 to 2.0) | 3.00 (2.0 to 6.0) | 2.00 (0.5 to 6.0) | 3.00 (2.0 to 24) |
| ng/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | 809 ± 41 | 709 ± 71 | 597 ± 38 | 579 ± 100 | 833 ± 49 | 743 ± 53 | 646 ± 24 |
| ng*h/mL | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | 11300 ± 21 | 7680 ± 88 | 6990 ± 38 | 6120 ± 110 | 12100 ± 58 | 8140 ± 58 | 10100 ± 44 |
Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| hours | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | NA (NA to NA) | NA (NA to NA) | 34.9 (29 to 44) | 36.5 (NA to NA) | 38.4 (27 to 52) | NA (NA to NA) | NA (NA to NA) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| CL/F of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | 11.5 ± 21 | 23.5 ± 88 | 18.6 ± 38 | 29.4 ± 110 | 20.3 ± 58 | 22.1 ± 58 | 24.2 ± 44 |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 18 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib |
|---|---|---|---|---|---|---|---|
| Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 1A All Cohorts | 1.64 ± 40 | 1.57 ± 45 | 1.89 ± 110 | 1.15 ± 55 | 1.56 ± 42 | 1.60 ± 100 | 1.46 ± 100 |
| hours | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts | 3.00 (2.0 to 6.0) | 2.00 (2.0 to 4.0) | 4.00 (2.0 to 24) | 4.00 (0 to 6.0) |
| ng/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts | 55 ± 160 | 123 ± 56 | 45.6 ± 110 | 77.8 ± 110 |
| ng*h/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 1B All Cohorts | 855 ± 150 | 1750 ± 77 | 699 ± 72 | 2460 ± NA |
| hours | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts | 5.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | 2.00 (0 to 6.0) | 6.00 (2.0 to 6.0) |
| ng/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts | 174 ± 50 | 232 ± 120 | 158 ± 73 | 245 ± 45 |
| ng*h/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts | 3270 ± 64 | 4320 ± 150 | NA ± NA | 4190 ± 52 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts | 12.2 ± 64 | 9.26 ± 150 | NA ± NA | 14.3 ± 52 |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 1B All Cohorts | 3.82 ± 60 | 2.46 ± 46 | NA ± NA | 1.15 ± 57 |
| hours | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts | 2.00 (2.0 to 2.0) | 2.00 (2.0 to 6.0) | 2.00 (2.0 to 24) | 4.00 (2.0 to 6.0) |
| ng/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts | 527 ± 67 | 609 ± 27 | 168 ± 130 | 363 ± 64 |
| ng*h/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 1B All Cohorts | 5380 ± 50 | 6540 ± 20 | 2260 ± 70 | 4160 ± 77 |
| hours | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts | 4.00 (0.5 to 6.0) | 2.00 (2.0 to 4.0) | 4.00 (2.0 to 6.0) | 5.00 (0 to 6.0) |
| ng/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts | 508 ± 10 | 1010 ± 27 | 227 ± 19 | 408 ± 62 |
| ng*h/mL | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts | 7000 ± 12 | 13500 ± 39 | NA ± NA | 5410 ± 57 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| CL/F of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts | 18.6 ± 12 | 13.3 ± 39 | NA ± NA | 33.3 ± 57 |
Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|
| Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 1B All Cohorts | 1.30 ± 40 | 2.06 ± 19 | NA ± NA | 1.36 ± 57 |
Stage 2 PK data were reported for each indication specific cohort separately.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts | 2.00 (2.0 to 6.0) | 4.00 (2.0 to 24) | 3.00 (2.0 to 6.0) | 4.00 (2.0 to 24) |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts | 73.8 ± 38 | 90.7 ± 87 | 116 ± 63 | 48.2 ± 97 |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2 All Cohorts | 1080 ± 26 | 1330 ± 100 | 1790 ± 73 | 700 ± 84 |
Stage 2 PK data were reported for each indication specific cohort separately.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 4.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | 2.00 (2.0 to 6.0) | NA (NA to NA) |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 119 ± 62 | 237 ± 63 | 254 ± 120 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 2200 ± 57 | 4570 ± 68 | 4700 ± 120 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| t1/2 of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 42.5 (40 to 45) | 51.5 (42 to 83) | 36.0 (28 to 44) | NA (NA to NA) |
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| CL/F of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 18.2 ± 57 | 8.76 ± 68 | 8.52 ± 120 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Accumulation Ratio of Cobimetinib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 1.92 ± 51 | 3.28 ± 52 | 2.60 ± 63 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts | 2.00 (2.0 to 6.0) | 2.00 (0.5 to 6.0) | 2.00 (0.5 to 4.0) | 4.00 (2.0 to 24) |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts | 298 ± 52 | 355 ± 55 | 315 ± 58 | 253 ± 90 |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2 Individual Indication Specific Cohorts | 3010 ± 37 | 3800 ± 63 | 3210 ± 59 | 3340 ± 78 |
Stage 2 PK data were reported for each indication specific cohort separately.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 4.00 (2.0 to 6.0) | 2.00 (0.5 to 6.0) | 2.00 (2.0 to 4.0) | NA (NA to NA) |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 231 ± 63 | 362 ± 60 | 369 ± 66 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 3390 ± 39 | 5250 ± 66 | 4580 ± 56 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
| hours | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| t1/2 of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 183 (NA to NA) | 28.5 (22 to 33) | 26.6 (20 to 37) | 30.9 (NA to NA) |
Stage 2 PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| L/hr | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| CL/F of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 29.5 ± 39 | 19.1 ± 66 | 21.8 ± 56 | NA ± NA |
Stage 2 PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1.
| ratio | S2 EGFR T790M NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS NSCLC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 KRAS CRC: 40 mg Cobimetinib + 100 mg Pictilisib | S2 Pancreatic: 40 mg Cobimetinib + 100 mg Pictilisib |
|---|---|---|---|---|
| Accumulation Ratio of Pictilisib on Cycle 1 Day 21 - Stage 2 Individual Indication Specific Cohorts | 0.90 ± 40 | 1.39 ± 58 | 1.43 ± 57 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 4.00 (NA to NA) | 6.00 (2.0 to 24.0) | 4.00 (2.0 to 24) | 4.00 (2.0 to 24) | 2.00 (2.0 to 4.0) |
Stage 2A PK data were reported for each indication specific cohort separately.
| ng/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 487 ± NA | 334 ± 44 | 256 ± 130 | 277 ± 110 | 408 ± 89 |
Stage 2A PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 6560 ± NA | 5210 ± 43 | 4470 ± 120 | 4090 ± 120 | 5630 ± 90 |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as median.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Tmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 4.00 (NA to NA) | 4.00 (2.0 to 6.0) | 3.00 (2.0 to 6.0) | 4.00 (2.0 to 6.0) | NA (NA to NA) |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Cmax of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 587 ± NA | 502 ± 16 | 469 ± 40 | 393 ± 44 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| AUC0-24 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 9560 ± NA | 7920 ± 16 | 7390 ± 32 | 5790 ± 46 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| t1/2 of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 37.7 (NA to NA) | 38.6 (33 to 42) | 50.2 (35 to 89) | 42.6 (27 to 64) | NA (NA to NA) |
Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| L/hr | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| CL/F of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 13.1 ± NA | 15.8 ± 16 | 16.9 ± 32 | 21.6 ± 46 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Accumulation Ratio of Cobimetinib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 1.46 ± NA | 1.43 ± 51 | 1.89 ± 94 | 1.72 ± 83 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 2.00 (NA to NA) | 2.00 (0.5 to 6.0) | 2.00 (0.5 to 6.0) | 2.00 (0.5 to 24) | 4.00 (2.0 to 6.0) |
Stage 2A PK data were reported for each indication specific cohort separately.
| ng/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 714 ± NA | 265 ± 140 | 289 ± 100 | 393 ± 90 | 369 ± 35 |
Stage 2A PK data were reported for each indication specific cohort separately.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 1 - Stage 2A Individual Indication Specific Cohorts | 8050 ± NA | 3380 ± 100 | 3310 ± 76 | 4030 ± 88 | 4500 ± 16 |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Tmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 2.00 (NA to NA) | 2.00 (2.0 to 24) | 2.00 (0.5 to 4.0) | 2.00 (2.0 to 6.0) | NA (NA to NA) |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Cmax of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 412 ± NA | 518 ± 67 | 520 ± 84 | 334 ± 83 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| AUC0-24 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 6300 ± NA | 6310 ± 31 | 5930 ± 73 | 3990 ± 74 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. Half-life is the time measured for the plasma concentration to decrease by one half.
| hours | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| t1/2 of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | — | 44.6 (28 to 66) | 58.2 (40 to 83) | 37.8 (29 to 50) | 30.3 (NA to NA) |
Stage 2A PK data were reported for each indication specific cohort separately. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| L/hr | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| CL/F of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 28.6 ± NA | 28.5 ± 31 | 30.3 ± 73 | 45.1 ± 74 | NA ± NA |
Stage 2A PK data were reported for each indication specific cohort separately. Accumulation ratio was calculated as: AUC0-24 at Cycle 1 Day 21 divided by AUC0-24 at Cycle 1 Day 1. As planned, summary statistics were not derived if fewer than 3 participants had available data; however, if the number of participants analyzed = 1, then the observed data of the single participant was reported as geometric mean.
| ng*h/mL | S2A EGFR T790M NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS NSCLC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A KRAS CRC: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Pancreatic: 125 mg Cobimetinib + 180 mg Pictilisib | S2A Endometrioid: 125 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|
| Accumulation Ratio of Pictilisib on Cycle 1 Day 18 - Stage 2A Individual Indication Specific Cohorts | 0.78 ± NA | 1.61 ± 110 | 1.90 ± 50 | 1.03 ± 84 | NA ± NA |
Tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) = disappearance of all target and non-target lesions. Partial Response (PR) = at least 30 percent (%) decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. Progressive disease (PD) = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions. Stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment start.
| participants | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SD | 2 | 2 | 1 | 15 | 5 | 3 | 1 | 0 | 2 | 3 | 16 | 5 | 2 | 0 | 1 | 1 | 0 | 1 |
| PD | 0 | 1 | 2 | 16 | 5 | 4 | 0 | 2 | 1 | 0 | 17 | 1 | 4 | 3 | 3 | 2 | 3 | 2 |
| Unable to Evaluate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Duration of objective response was defined as the time from first occurrence of a documented objective response (CR or PR) until the time of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). CR = disappearance of all target and non-target lesions. PR = at least 30 % decrease in sum of the longest diameter of measured lesions taking as reference the baseline sum of the longest diameter. PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.
No measurements were reported for this outcome.
PFS was the time from study treatment initiation to the first occurrence of disease progression, as determined by investigator review of tumor assessments using RECIST, or death from any cause during the study (within 30 days after the last dose of study treatment). PD = at least 20% increase in the sum of the longest diameter of measured lesions taking as reference the smallest sum of the longest diameter since treatment start or appearance of one or more new lesions.
No measurements were reported for this outcome.
Collected over Up to 30 days after last dose (last dose = up to Cycle 15, cycle length = 28 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | — | 2/4 (50%) | 4/4 (100%) |
| S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | — | 0/3 (0%) | 3/3 (100%) |
| S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | — | 1/3 (33.3%) | 3/3 (100%) |
| S1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | — | 25/43 (58.1%) | 42/43 (97.7%) |
| S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | — | 6/11 (54.5%) | 11/11 (100%) |
| S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | — | 6/10 (60%) | 10/10 (100%) |
| S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | — | 2/4 (50%) | 4/4 (100%) |
| S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | — | 2/3 (66.7%) | 3/3 (100%) |
| S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | — | 2/3 (66.7%) | 3/3 (100%) |
| S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | — | 3/4 (75%) | 4/4 (100%) |
| S1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg Pictilisib | — | 28/52 (53.8%) | 52/52 (100%) |
| S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | — | 4/9 (44.4%) | 9/9 (100%) |
| S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | — | 5/8 (62.5%) | 8/8 (100%) |
| S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | — | 3/5 (60%) | 5/5 (100%) |
| S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | — | 0/4 (0%) | 4/4 (100%) |
| S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | — | 0/3 (0%) | 3/3 (100%) |
| S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | — | 0/3 (0%) | 3/3 (100%) |
| S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib | — | 2/5 (40%) | 5/5 (100%) |
| Event | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 1/43 | 0/11 | 4/10 | 1/4 | 0/3 | 0/3 | 1/4 | 3/52 | 0/9 | 2/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Bile duct obstructionHepatobiliary disorders | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 0/3 | 1/3 | 0/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| PneumoniaInfections and infestations | 1/4 | 0/3 | 1/3 | 2/43 | 0/11 | 0/10 | 0/4 | 0/3 | 0/3 | 0/4 | 2/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| SepsisInfections and infestations | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 1/3 | 0/3 | 0/4 | 2/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Blood bilirubin increasedInvestigations | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 1/3 | 0/3 | 0/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Gastrooesophageal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 1/3 | 0/3 | 0/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Urinary retentionRenal and urinary disorders | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 0/3 | 1/3 | 0/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 1/3 | 0/43 | 0/11 | 0/10 | 0/4 | 0/3 | 0/3 | 0/4 | 1/52 | 1/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Urinary tract infectionInfections and infestations | 0/4 | 0/3 | 1/3 | 0/43 | 0/11 | 0/10 | 0/4 | 0/3 | 0/3 | 0/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Cardiac arrestCardiac disorders | 0/4 | 0/3 | 0/3 | 0/43 | 0/11 | 0/10 | 0/4 | 0/3 | 0/3 | 1/4 | 0/52 | 0/9 | 0/8 | 0/5 | 0/4 | 0/3 | 0/3 | 0/5 |
| Event | S1 C1: 20 mg Cobimetinib + 80 mg Pictilisib | S1 C2: 20 mg Cobimetinib + 100 mg Pictilisib | S1 C3: 40 mg Cobimetinib + 80 mg Pictilisib | S1 C4/S2 Expansion: 40 mg Cobimetinib + 100 mg Pictilisib | S1 C5: 40 mg Cobimetinib + 130 mg Pictilisib | S1 C6: 60 mg Cobimetinib + 100 mg Pictilisib | S1 C6A: 80 mg Cobimetinib + 100 mg Pictilisib | S1A CA: 100 mg Cobimetinib + 130 mg Pictilisib | S1A CB: 100 mg Cobimetinib + 180 mg Pictilisib | S1A CC: 125 mg Cobimetinib + 130 mg Pictilisib | S1A CD/S2A Expension: 125 mg Cobimetinib + 180 mg Pictilisib | S1A CE: 125 mg Cobimetinib + 245 mg Pictilisib | S1A CF: 150 mg Cobimetinib + 180 mg Pictilisib | S1A CG: 150 mg Cobimetinib + 245 mg Pictilisib | S1B CAX: 40 mg Cobimetinib + 130 mg Pictilisib | S1B CBX: 40 mg Cobimetinib + 180 mg Pictilisib | S1B CCX: 60 mg Cobimetinib + 130 mg Pictilisib | S1B CDX: 60 mg Cobimetinib + 180 mg Pictilisib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/4 | 3/3 | 3/3 | 39/43 | 9/11 | 8/10 | 4/4 | 2/3 | 3/3 | 4/4 | 44/52 | 8/9 | 7/8 | 4/5 | 3/4 | 2/3 | 3/3 | 3/5 |
| NauseaGastrointestinal disorders | 3/4 | 2/3 | 3/3 | 25/43 | 6/11 | 6/10 | 3/4 | 1/3 | 3/3 | 3/4 | 36/52 | 7/9 | 7/8 | 3/5 | 1/4 | 2/3 | 1/3 | 5/5 |
| StomatitisGastrointestinal disorders | 0/4 | 0/3 | 0/3 | 11/43 | 1/11 | 3/10 | 2/4 | 1/3 | 3/3 | 2/4 | 12/52 | 4/9 | 1/8 | 1/5 | 0/4 | 0/3 | 1/3 | 1/5 |
| VomitingGastrointestinal disorders | 3/4 | 0/3 | 2/3 | 27/43 | 5/11 | 8/10 | 3/4 | 2/3 | 0/3 | 4/4 | 32/52 | 5/9 | 6/8 | 3/5 | 0/4 | 3/3 | 1/3 | 4/5 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 0/3 | 1/3 | 16/43 | 3/11 | 5/10 | 1/4 | 1/3 | 3/3 | 4/4 | 21/52 | 3/9 | 5/8 | 2/5 | 2/4 | 1/3 | 1/3 | 2/5 |
| DysgeusiaNervous system disorders | 0/4 | 1/3 | 0/3 | 16/43 | 3/11 | 2/10 | 0/4 | 2/3 | 3/3 | 1/4 | 16/52 | 3/9 | 5/8 | 2/5 | 2/4 | 2/3 | 1/3 | 1/5 |
| RashSkin and subcutaneous tissue disorders | 0/4 | 2/3 | 2/3 | 9/43 | 8/11 | 2/10 | 3/4 | 0/3 | 3/3 | 2/4 | 19/52 | 3/9 | 1/8 | 0/5 | 1/4 | 0/3 | 1/3 | 0/5 |
| FatigueGeneral disorders | 3/4 | 1/3 | 1/3 | 26/43 | 5/11 | 5/10 | 3/4 | 1/3 | 2/3 | 2/4 | 29/52 | 6/9 | 7/8 | 3/5 | 3/4 | 1/3 | 2/3 | 2/5 |
| HeadacheNervous system disorders | 2/4 | 1/3 | 0/3 | 7/43 | 2/11 | 1/10 | 0/4 | 0/3 | 0/3 | 0/4 | 7/52 | 2/9 | 0/8 | 4/5 | 0/4 | 0/3 | 1/3 | 0/5 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/4 | 0/3 | 0/3 | 16/43 | 3/11 | 3/10 | 0/4 | 1/3 | 0/3 | 1/4 | 12/52 | 4/9 | 3/8 | 4/5 | 0/4 | 1/3 | 1/3 | 1/5 |
All enrolled participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 56.6 ± 12.0 |
| Gender(Participants) | All Participants |
|---|---|
| Female | 109 |
| Male | 69 |
The record gives a start of Nov 2009, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cobimetinib · Pictilisib
Hereditary Sensory and Autonomic Neuropathies